Actuate Therapeutics Shares Down 49.2%; Q4 Results Slated for March 12
Actuate Therapeutics shares have fallen 49.2% over the past 12 months, reflecting significant investor caution. The company is set to report fourth-quarter 2025 results on March 12 and currently holds a Zacks Rank #2 (Buy).
1. Share Performance Decline
Shares of Actuate Therapeutics have dropped by 49.2% in the trailing 12 months, underperforming broader medical sector indices and signaling investor concern over recent operational progress and pipeline developments.
2. Upcoming Fourth-Quarter Report
The company is scheduled to release fourth-quarter 2025 financial results on March 12, with analysts monitoring revenue guidance, clinical milestone updates and cash runway projections ahead of the report.
3. Analyst Ranking and Outlook
Actuate Therapeutics holds a Zacks Rank #2 (Buy), suggesting positive earnings revision trends; investors will watch for any upward or downward adjustments following the Q4 release to gauge near-term stock momentum.